IONS Stock Summary and Trading Ideas (Ionis Pharmaceuticals | NASDAQ:IONS)

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

What symbol and exchange does Ionis Pharmaceuticals shares trade?

Ionis Pharmaceuticals trades on the NASDAQ stock market under the symbol IONS.

What is Ionis Pharmaceuticals stock price doing today?

As of May 1, 2026, IONS stock price climbed to $75.28 with 1,590,326 million shares trading.

What is Ionis Pharmaceuticals's Beta?

IONS has a beta of 0.98, meaning it tends to be less sensitive to market movements. IONS has a correlation of 0.10 to the broad based SPY ETF.

How much is Ionis Pharmaceuticals worth?

IONS has a market cap of $12.43 billion. This is considered a Large Cap stock.

How much money does Ionis Pharmaceuticals make?

Last quarter Ionis Pharmaceuticals reported $246 million in Revenue and -$.30 earnings per share. This beat revenue expectation by $51 million and exceeded earnings estimates by $.50.

What is the highest and lowest price Ionis Pharmaceuticals traded in the last 3 year period?

In the last 3 years, IONS traded as high as $86.74 and as low as $23.95.

What are the top ETFs holding Ionis Pharmaceuticals?

The top ETF exchange traded funds that IONS belongs to (by Net Assets): VTI, VB, VBK, VXF, XBI.

Is Ionis Pharmaceuticals (IONS) a good investment?

IONS has outperformed the market in the last year with a return of +145.1%, while the SPY ETF gained +31.3%. However, in the most recent history, IONS shares have underperformed the stock market with its stock returning -8.9% in the last 3 month period and 0.0% for the last 2 week period, while SPY has returned +4.4% and +2.7%, respectively.

What are the support and resistance levels for Ionis Pharmaceuticals (IONS)?

IONS support price is $73.32 and resistance is $76.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IONS shares will trade within this expected range on the day.